These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 36041258)
1. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. Wang Q; Zhang J Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258 [TBL] [Abstract][Full Text] [Related]
2. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. Li Y; Liu CF; Rao GW Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505 [TBL] [Abstract][Full Text] [Related]
3. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876 [TBL] [Abstract][Full Text] [Related]
5. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287 [TBL] [Abstract][Full Text] [Related]
6. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340 [TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Zeng Y; Arisa O; Peer CJ; Fojo A; Figg WD Semin Oncol; 2024; 51(1-2):19-24. PubMed ID: 37880048 [TBL] [Abstract][Full Text] [Related]
10. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Wang L; Wang Q; Xu Y; Cui M; Han L Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293 [TBL] [Abstract][Full Text] [Related]
11. PARP and PARG inhibitors in cancer treatment. Slade D Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455 [TBL] [Abstract][Full Text] [Related]
12. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. Chen Y; Du H Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102 [TBL] [Abstract][Full Text] [Related]
14. Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. Liu F; Chen J; Li X; Liu R; Zhang Y; Gao C; Shi D J Med Chem; 2023 Dec; 66(24):16464-16483. PubMed ID: 38088333 [TBL] [Abstract][Full Text] [Related]
15. The DNA damaging revolution. Cetin B; Wabl CA; Gumusay O Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228 [TBL] [Abstract][Full Text] [Related]
16. Veliparib: a new therapeutic option in ovarian cancer? Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636 [TBL] [Abstract][Full Text] [Related]
17. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy. Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810 [TBL] [Abstract][Full Text] [Related]
18. A review on mechanisms of resistance to PARP inhibitors. Desai C; Pathak A; Limaye S; Maniar V; Joshi A Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196 [TBL] [Abstract][Full Text] [Related]
19. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284 [TBL] [Abstract][Full Text] [Related]
20. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Gunderson CC; Moore KN Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]